FDA Lifts Clinical Hold on Filana's Simufilam, Clearing Phase 2a Trial in TSC-Related Epilepsy
核心洞察
The FDA has lifted a clinical hold on Filana Therapeutics (搜索)' IND for simufilam, allowing a Phase 2a proof-of-concept study in TSC-related epilepsy (搜索) to proceed.
The 16-week randomized, double-blind trial will test two simufilam doses at 13 U.S. sites in 40 patients aged 12 to 55 with refractory seizures.
Simufilam modulates filamin A (搜索) and is supported by two preclinical mouse studies, including one showing dose-dependent attenuation of seizure progression.
Filana Therapeutics (搜索) said the U.S. Food and Drug Administration has lifted the clinical hold on its investigational new drug application for simufilam, clearing the company to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with tuberous sclerosis complex (搜索) (TSC)-related epilepsy. Patient screening is expected to begin by the first quarter of 2027.
The hold was placed in December 2025, when the FDA requested additional preclinical data and protocol changes. The lift, confirmed September 22, allows the trial to proceed under a revised protocol that satisfied the agency's preclinical data requirements.
"With the clinical hold lifted, we can now execute our development plan for simufilam in TSC-related epilepsy (搜索)," said Rick Barry, President and Chief Executive Officer of Filana. "While on hold, we completed key trial-readiness activities, including engaging a leading clinical research organization, identifying clinical trial sites, and recruiting potential investigators. With investigational drug supply in place, implementation of our Phase 2a study of simufilam is now able to progress expeditiously toward site initiation and patient enrollment."
Trial Design and Endpoints
The Phase 2a study is a 16-week multicenter, randomized, double-blind trial evaluating two doses of simufilam in patients with refractory TSC-related seizures. It is planned at 13 sites in the United States with a target enrollment of 40 subjects aged 12 to 55. All subjects who complete the double-blind treatment phase are eligible to participate in a 48-week extension study.
The study is designed to assess safety, tolerability, pharmacokinetics, and seizure-related measures, including seizure frequency, seizure intensity and duration, nighttime seizures, and sleep-related outcomes. Filana said data from the study are expected to inform the development path for simufilam in TSC-related epilepsy (搜索), including the design of future studies in younger patient populations.
Mechanism and Preclinical Rationale
Simufilam is an oral small molecule intended to modulate the filamin A (搜索) protein. The clinical evaluation in TSC-related epilepsy (搜索) is supported by findings from two preclinical mouse models. Initial studies were conducted in the laboratory of Angélique Bordey, PhD, Rothberg Professor of Neurosurgery at Yale School of Medicine and Senior Vice President, Neuroscience at Filana. Those studies showed that simufilam reduced seizure frequency in a mouse model of focal onset seizures involving TSC-related pathology.
In a separate study conducted with the TSC Alliance (搜索) Preclinical Consortium using a TSC-knockout mouse model, simufilam attenuated the progression of seizure activity in a dose-dependent manner. Filana holds an exclusive worldwide license from Yale University (搜索) to intellectual property supporting the use of simufilam in TSC-related epilepsy (搜索).
A Different Indication After Alzheimer's Failure
Simufilam was originally developed by Cassava Sciences (搜索) for Alzheimer's disease (搜索), where it failed to hit co-primary, secondary, or exploratory biomarker endpoints across two Phase 3 trials, RETHINK-ALZ and REFOCUS-ALZ, leading Cassava to shut down that program entirely by early 2025. Filana is now pursuing a different indication, betting that the biology simufilam engages is relevant to the seizure pathophysiology of TSC rather than Alzheimer's neurodegeneration. That mechanistic pivot is unproven, and the Phase 2a study is explicitly a proof-of-concept read, not a registration-enabling trial.
Unmet Need in TSC-Related Epilepsy
TSC is a rare genetic disorder resulting from a mutation in the TSC1 (搜索) or TSC2 (搜索) gene. These mutations affect the mechanistic target of rapamycin (mTOR (搜索)) pathway and can cause tumors to grow in multiple organs. Epilepsy is the most common health issue affecting the TSC community, with 80% to 90% of TSC patients experiencing seizures. TSC-related epilepsy (搜索) affects approximately 45,000 people in the U.S., and most patients start having seizures within their first year of life.
Even with multiple approved treatments, more than 60% of TSC patients remain refractory to antiepileptic therapy. Everolimus (Afinitor Disperz) is approved as adjunctive therapy for partial-onset refractory seizures in patients two years and older, based on the EXIST-3 trial. A meaningful share of TSC patients continue to have refractory seizures despite mTOR (搜索) inhibition and other available agents.
"Drug-resistant epilepsy remains a challenge for a majority of individuals affected by TSC," said Kari Luther Rosbeck, President and Chief Executive Officer of the TSC Alliance (搜索). "Research investigating different molecular pathways involved in TSC offers hope for potential new options for those living with the disease. The TSC Alliance applauds Filana for their innovative work in exploring a new target mechanism and their plans to launch a clinical trial to test the effectiveness of that potential new treatment to help address a major unmet need for the TSC community."
Filana said it is collaborating with the TSC Alliance (搜索) and the broader TSC community to support patient engagement and study execution. Simufilam remains an investigational product candidate and has not been approved for use in any medical indication by any regulatory authority.